A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer

Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BE...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yundong He, Ting Wei, Zhenqing Ye, Jacob J. Orme, Dong Lin, Haoyue Sheng, Ladan Fazli, R. Jeffrey Karnes, Rafael Jimenez, Liguo Wang, Liewei Wang, Martin E. Gleave, Yuzhuo Wang, Lei Shi, Haojie Huang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/00b4af7118804738bdce75145ea247c5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:00b4af7118804738bdce75145ea247c5
record_format dspace
spelling oai:doaj.org-article:00b4af7118804738bdce75145ea247c52021-12-02T15:52:50ZA noncanonical AR addiction drives enzalutamide resistance in prostate cancer10.1038/s41467-021-21860-72041-1723https://doaj.org/article/00b4af7118804738bdce75145ea247c52021-03-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-21860-7https://doaj.org/toc/2041-1723Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BET and CBP/p300 signaling.Yundong HeTing WeiZhenqing YeJacob J. OrmeDong LinHaoyue ShengLadan FazliR. Jeffrey KarnesRafael JimenezLiguo WangLiewei WangMartin E. GleaveYuzhuo WangLei ShiHaojie HuangNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
institution DOAJ
collection DOAJ
language EN
topic Science
Q
spellingShingle Science
Q
Yundong He
Ting Wei
Zhenqing Ye
Jacob J. Orme
Dong Lin
Haoyue Sheng
Ladan Fazli
R. Jeffrey Karnes
Rafael Jimenez
Liguo Wang
Liewei Wang
Martin E. Gleave
Yuzhuo Wang
Lei Shi
Haojie Huang
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
description Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BET and CBP/p300 signaling.
format article
author Yundong He
Ting Wei
Zhenqing Ye
Jacob J. Orme
Dong Lin
Haoyue Sheng
Ladan Fazli
R. Jeffrey Karnes
Rafael Jimenez
Liguo Wang
Liewei Wang
Martin E. Gleave
Yuzhuo Wang
Lei Shi
Haojie Huang
author_facet Yundong He
Ting Wei
Zhenqing Ye
Jacob J. Orme
Dong Lin
Haoyue Sheng
Ladan Fazli
R. Jeffrey Karnes
Rafael Jimenez
Liguo Wang
Liewei Wang
Martin E. Gleave
Yuzhuo Wang
Lei Shi
Haojie Huang
author_sort Yundong He
title A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
title_short A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
title_full A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
title_fullStr A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
title_full_unstemmed A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
title_sort noncanonical ar addiction drives enzalutamide resistance in prostate cancer
publisher Nature Portfolio
publishDate 2021
url https://doaj.org/article/00b4af7118804738bdce75145ea247c5
work_keys_str_mv AT yundonghe anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT tingwei anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT zhenqingye anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT jacobjorme anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT donglin anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT haoyuesheng anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT ladanfazli anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT rjeffreykarnes anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT rafaeljimenez anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT liguowang anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT lieweiwang anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT martinegleave anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT yuzhuowang anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT leishi anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT haojiehuang anoncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT yundonghe noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT tingwei noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT zhenqingye noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT jacobjorme noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT donglin noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT haoyuesheng noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT ladanfazli noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT rjeffreykarnes noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT rafaeljimenez noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT liguowang noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT lieweiwang noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT martinegleave noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT yuzhuowang noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT leishi noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
AT haojiehuang noncanonicalaraddictiondrivesenzalutamideresistanceinprostatecancer
_version_ 1718385550628487168

Ejemplares similares